Top 3 Health Care Stocks That May Explode In July - HCA Healthcare ( NYSE:HCA ) , Molina Healthcare ( NYSE:MOH )
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.
NovoCure Q2 Revenue Jumps 6 Percent
NovoCure ( NASDAQ:NVCR ) , the oncology device firm advancing Tumor Treating Fields therapy, released its second quarter 2025 results on July 24, 2025. GAAP revenue totaled $158.8 million in Q2 2025, an increase of 6% year over year and surpassing the $154.16 million analyst consensus ( GAAP ) .
Novocure: Steady Ahead of Key Milestones
Here's our initial take on Novocure's ( NASDAQ: NVCR ) fiscal 2025 second-quarter financial report.Novocure reported no surprises in its latest quarter, with revenue up 6% for the year and both revenue and loss per share topping Wall Street expectations.
NovoCure ( NVCR ) Reports Q2 Loss, Tops Revenue Estimates
NovoCure (NVCR) delivered earnings and revenue surprises of +7.69% and +3.24%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
This Circle Internet Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Tuesday - BrightSpire Capital ( NYSE:BRSP ) , Bluerock Homes Trust ( AMEX:BHM )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
NovoCure ( NVCR ) Soars 5.3%: Is Further Upside Left in the Stock?
NovoCure (NVCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
What Makes NovoCure ( NVCR ) a New Buy Stock
NovoCure (NVCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial
Novocure's PANOVA-3 trial shows that the TTFields combo boosts survival in pancreatic cancer, hitting the primary endpoint.
NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial - NovoCure ( NASDAQ:NVCR ) , Zai Lab ( NASDAQ:ZLAB )
Median overall survival improved to 16.2 months with TTFields vs. 14.2 months for standard treatment. TTFields extended pain-free survival by 6.1 months, reaching a median of 15.2 months. Ready to turn the market's comeback into steady cash flow? Grab the top 3 stocks to buy right here.
1 Stock Down 35% This Year You'll Regret Not Buying on the Dip, According to Wall Street
It's been a challenging year for NovoCure ( NASDAQ: NVCR ) , an oncology-focused biotech. The stock is down by 35% since early January. Though marketwide issues probably didn't help, NovoCure mostly has itself to blame for its year-to-date performance.
Does NovoCure ( NVCR ) Have the Potential to Rally 105.5% as Wall Street Analysts Expect?
The mean of analysts' price targets for NovoCure (NVCR) points to a 105.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts See a 91.92% Upside in NovoCure ( NVCR ) : Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 91.9% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Why NovoCure Stock Skyrocketed This Week
Shares of NovoCure ( NASDAQ: NVCR ) are edging higher on Thursday. The company's stock gained 0.11% as of 3:30 p.m. ET after fluctuating between gains and losses throughout the session. This muted reaction comes as the S&P 500 gained 0.3% and the Nasdaq Composite rose 0.6%.Why?
Why NovoCure Stock Leaped 4% Higher Today
Thursday morning NovoCure ( NASDAQ: NVCR ) published its first set of quarterly results for 2025, and they pleased more than a few investors. With that tailwind, the biotech's stock price rose in excess of 4%, easily topping the slightly over 2% increase of the S&P 500 index.For the first ...
NovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 2025 - NovoCure ( NASDAQ:NVCR )
Q1 revenue rose 12% YoY to $155 million, beating the $146.6 million consensus. Optune Gio active patients grew 9% YoY to 4,162 worldwide. Today's manic market swings are creating the perfect setup for Matt's next volatility trade. Get his next trade alert for free, right here.
NovoCure Surpasses Q1 Expectations
NovoCure posted stronger-than-expected Q1 2025 results, driven by revenue and GAAP earnings surpassing estimates.
NovoCure ( NVCR ) Reports Q1 Loss, Tops Revenue Estimates
NovoCure (NVCR) delivered earnings and revenue surprises of 34.04% and 5.03%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Exelixis ( EXEL ) Earnings Expected to Grow: What to Know Ahead of Q1 Release
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NovoCure ( NVCR ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
NovoCure (NVCR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why NovoCure Stock Was Withering on Wednesday
Cancer-focused biotech NovoCure ( NASDAQ: NVCR ) was the focus of a stock price target cut on Wednesday, and investors weren't particularly happy about it.They expressed their displeasure by selling out of their positions, to the point where the company's stock was down by nearly 5% in ...
Strength Seen in Bio-Techne ( TECH ) : Can Its 10.8% Jump Turn into More Strength?
Bio-Techne (TECH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
NovoCure ( NVCR ) Q4 2024 Earnings Call Transcript
NVCR earnings call for the period ending December 31, 2024.
NovoCure Reports Wider Than Expected Q4 Loss Despite 21% Jump In Sales, Expects Product Enhancements To Hit Gross Margin In 2025 - NovoCure ( NASDAQ:NVCR )
NovoCure reported a Q4 loss of $0.61 per share, missing estimates, while revenue rose 21% to $161.27M, beating the consensus. Annual sales grew to $605 million, driven by Optune Gio's launch in France. Our government trade tracker caught Pelosi's 169% AI winner.
NovoCure Q4 EPS Misses, Revenue Matches
NovoCure reported a solid jump in revenue, but earnings fell short due to rising costs and adoption challenges.
NovoCure ( NVCR ) Reports Q4 Loss, Misses Revenue Estimates
NovoCure (NVCR) delivered earnings and revenue surprises of -79.41% and 0.02%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
PathMaker Neurosystems Welcomes Pritesh Shah to Board of Directors
BOSTON, Feb. 26, 2025 ( GLOBE NEWSWIRE ) -- PathMaker Neurosystems Inc. ( "PathMaker" ) , a clinical-stage neuromodulation company pioneering a breakthrough non-invasive treatment approach for amyotrophic lateral sclerosis ( ALS ) , is pleased to announce the appointment of Pritesh Shah, ...
NovoCure ( NVCR ) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Jim Cramer Likes This Tech Stock: 'Terrific Business, Niche Business' - Keysight Techs ( NYSE:KEYS ) , ADMA Biologics ( NASDAQ:ADMA )
"I don't have a catalyst," Jim Cramer on ADMA Biologics. "Terrific business, niche business," Cramer on Keysight. Get Wall Street's Hottest Chart Every Morning On CNBC's "Mad Money Lightning Round," Jim Cramer said he likes Keysight Technologies, Inc.
Should You Invest in the SPDR S&P Health Care Equipment ETF ( XHE ) ?
Sector ETF report for ...
Why NovoCure Stock Was Winning Big This Week
Cancer-targeting biotech NovoCure ( NASDAQ: NVCR ) had some highly positive news from the laboratory to deliver earlier this week, and investors couldn't grab hold of the stock fast enough. This momentum was helped by price target increases from analysts.
Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025?
The life science industry recently gave folks diagnosed with pancreatic cancer the best news this group has received in a very long time. A new treatment option that significantly raises their chances for long-term survival could become widely available next year.Novocure ( NASDAQ: NVCR ) and its ...
NVCR Stock Up as TTFields Therapy Meets Pancreatic Cancer Study Goals
Novocure stock soars 49% as the late-stage study of TTFields therapy for treating pancreatic adenocarcinoma meets the primary endpoint of overall survival.
Dow Dips 150 Points; ISM Manufacturing PMI Tops Estimates - NovoCure ( NASDAQ:NVCR ) , Mondee Hldgs ( NASDAQ:MOND )
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 150 points on Monday. The Dow traded down 0.34% to 44,759.96 while the NASDAQ gained 1.03% to 19,416.22. The S&P 500 also rose, gaining, 0.26% to 6,047.97. Communication services shares jumped by 1% on Tuesday.
XPeng, NovoCure, Merus, Gap And Other Big Stocks Moving Higher On Monday - Akso Health ( NASDAQ:AHG ) , Abercrombie & Fitch ( NYSE:ANF )
U.S. stocks were mixed, with the Dow Jones index falling more than 100 points on Monday. Shares of XPeng Inc. XPEV rose sharply during Monday's session. The company delivered 30,895 vehicles last month, marking an increase of 54% year-over-year and 29% from October.
NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients - NovoCure ( NASDAQ:NVCR ) , Zai Lab ( NASDAQ:ZLAB )
On Monday, NovoCure Ltd NVCR and Zai Lab Limited ZLAB revealed topline data from the Phase 3 PANOVA-3 trial of Tumor-Treating Fields ( TTFields ) therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma.
This Gap Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday - Gap ( NYSE:GAP ) , Akamai Techs ( NASDAQ:AKAM )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
NovoCure ( NVCR ) Q3 2024 Earnings Call Transcript
NVCR earnings call for the period ending September 30, 2024.
NovoCure ( NVCR ) Reports Q3 Loss, Tops Revenue Estimates
NovoCure (NVCR) delivered earnings and revenue surprises of 17.65% and 7.60%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Nasdaq, S&P 500 Futures Edge Up After Tuesday's Chip Sell-off - Invesco QQQ Trust, Series 1 ( NASDAQ:QQQ ) , SPDR S&P 500 ( ARCA:SPY )
U.S. stock futures point to a flattish start on Wednesday after the S&P 500 Index and the Dow Jones Industrial Average retreated from record highs in the previous session.
NovoCure ( NVCR ) Surges 10.7%: Is This an Indication of Further Gains?
NovoCure (NVCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Why NovoCure Stock Dived by 13% This Week
Investors found the announced changes to the company's C-suite unsettling.
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - Intel ( NASDAQ:INTC )
Shares of Recursion Pharmaceuticals, Inc. RXRX dipped 11.6% to $6.43. The company on Tuesday announced Phase 2 data for an investigational treatment for symptomatic Cerebral Cavernous Malformation ( CCM ) . Nikola shares dipped 10.4% to $7.28 on Monday.
Wall Street Analysts Think NovoCure ( NVCR ) Could Surge 35.96%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 36% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Chips, Glorious Chips!
Someone's gotta make 'em, and someone's gotta buy 'em.
New Strong Buy Stocks for August 1st
NVCR, KGC, CVNA, KNSA and MU have been added to the Zacks Rank #1 (Strong Buy) List on August 1, 2024.
PayPal Posts Upbeat Earnings, Joins Sprouts Farmers Market, Stanley Black & Decker, Phillips 66 And Other Big Stocks Moving Higher On Tuesday - PayPal Holdings ( NASDAQ:PYPL )
U.S. stocks were mixed, with the Dow Jones index gaining more than 100 points on Tuesday. Shares of PayPal Holdings, Inc. PYPL rose sharply during Tuesday's session after the company reported better-than-expected second quarter financial results.
Wall Street Analysts Believe NovoCure ( NVCR ) Could Rally 26.39%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 26.4% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
NovoCure's Q2 Revenue Soars by 10.7%
The oncology treatment pioneer delivered a robust report showcasing significant revenue growth and a clinical trial success.
NovoCure ( NVCR ) Q2 2024 Earnings Call Transcript
NVCR earnings call for the period ending June 30, 2024.
NovoCure ( NVCR ) Reports Q2 Loss, Tops Revenue Estimates
NovoCure (NVCR) delivered earnings and revenue surprises of 22.50% and 10.18%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
